Breaking News
Get 40% Off 0
Join +750K new investors every month who copy stock picks from billionaire's portfolios Sign Up Free
Close

Novartis AG (NOVN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
95.01 +0.75    +0.80%
14/06 - Closed. Currency in CHF ( Disclaimer )
Type:  Equity
Market:  Switzerland
ISIN:  CH0012005267 
VALOR:  1200526
  • Volume: 3,143,025
  • Bid/Ask: 95.00 / 95.09
  • Day's Range: 94.03 - 95.26
Novartis 95.01 +0.75 +0.80%

Novartis AG Company Profile

 
Get an in-depth profile of Novartis AG, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

76057

Equity Type

ORD

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Contact Information

Address Lichtstrasse 35
Basel, 4056
Switzerland
Phone 41 61 324 1111
Fax 41 61 324 8001

Top Executives

Name Age Since Title
Joerg Reinhardt 66 1999 Independent Non-Executive Chairman
Daniel L. Vasella 69 1996 Honorary Chairman
Simon E. Moroney 63 2020 Independent Vice Chairman of the Board
Ton Buechner 57 2016 Independent Non-Executive Director
Elizabeth Doherty 65 2016 Independent Non-Executive Director
Patrice Bula 66 2019 Lead Independent Director
Nancy C. Andrews 65 2015 Independent Non-Executive Director
Daniel Hochstrasser - 2022 Independent Director
François Adrianus van Houten 63 2017 Independent Non-Executive Director
Charles L. Sawyers 64 2013 Independent Non-Executive Director
William Thomas Winters 62 2013 Independent Non-Executive Director
Bridgette P. Heller 62 2020 Independent Non-Executive Director
John D. Young 60 2023 Non-Executive & Independent Director
Ana de Pro Gonzalo 57 2022 Non-Executive & Independent Director
Sidonie Golombowski-Daffner - - Chairperson & President of Advanced Accelerator Applications
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NOVN Comments

Write your thoughts about Novartis AG
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Pablo Germain
Pablo Germain Jan 10, 2023 1:48PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Could someone explain to me today's -2%?
Mr Ride
MrRide Jan 10, 2023 1:48PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Citi analyst downgraded Novartis (SW) (NVS) from Buy to Neutral with a price target of CHF86.00 (from CHF95.00).
Chemsedine Bendaci
Chemsedine Bendaci Feb 02, 2022 2:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
great results coming
Chemsedine Bendaci
Chemsedine Bendaci Jan 12, 2022 6:20AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
price target 116.34 according to zone bourse
Michael Näf
Michael Näf Feb 24, 2021 6:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Now good price to go in!
Vima OG
Vima OG Feb 26, 2020 11:38AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Long term.
Kristof Mouton
Stoffel Sep 17, 2019 4:40PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
before investing in @novartis, read #teampia (twitter).
MoneyManager MoneyManager
Money2Manage4U Sep 17, 2019 4:40PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what refers ?
José Spescha
José Spescha Sep 17, 2019 4:40PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I can not open #teampia. What is the conclusion?
Toni Fluxá
Toni Fluxá Apr 10, 2019 8:14AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
botton at 81
Levo Goldberg
Levo Goldberg Apr 10, 2019 8:14AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hope so loaded heavily at 85....
Brunello Pianca
Brunello Pianca Jan 15, 2019 12:13PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
must hold 83.50 for uptrend to resume
Tomas Lysak DiS
Tomas Lysak DiS Aug 23, 2018 7:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
yes. Novartis is a good company with solid numbers.
Shadow Trader
ShadowTrader Sep 10, 2017 8:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nice time to buy ? I'm not pretty sure... any one can say something about. ?. thanks to all
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email